A few months ago, the Food and Drug Administration approved the first JAK Inhibitor for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
Concerns Raised About Lack of Continuity of Care for VA’s IBD Patients
The lack of continuity of care among VA patients with inflammatory bowel disease (IBD) is associated with poor outcomes, such as disease flares requiring corticosteroid treatment, hospitalization and surgical intervention.
New Program Helps Transitioning Servicemembers with Inflammatory Bowel Disease
Delays in VA Appointments Pose Challenges SAN ANTONIO, TX — A new program at the Brooke Army Medical Center at Fort Sam Houston aims to give transitioning servicemembers with inflammatory bowel disease the information they need to manage their disease when they leave...